A. Brize

发表

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

V. Valero, H. Rugo, S. Dakhil, 2012, Breast Cancer Research and Treatment.

A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.

M. Buyse, I. Vergote, H. Bjermo, 2019, Gynecologic oncology.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

B. Monk, B. Karlan, A. Oza, 2014 .

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

B. Monk, B. Karlan, A. Oza, 2015 .

Randomized phase III study comparing paclical-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer.

I. Vergote, M. Lichinitser, A. Brize, 2015 .

Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel

R. Vyzula, J. Abrahámová, J. Jassem, 2010, Wiener klinische Wochenschrift.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

B. Monk, B. Karlan, A. Oza, 2014, The Lancet. Oncology.

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

R. Huddart, E. Gallardo, N. Agarwal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2.

V. Valero, H. Rugo, S. Dakhil, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Nanoparticle micellar formulation of paclitaxel in combination with carboplatin for women with recurrent platinum sensitive ovarian cancer (OAS07-OVA): Overall survival results of a phase 3 randomized trial.

I. Vergote, H. Bjermo, A. Brize, 2018 .